ERCC6L2 and myelodysplastic syndrome: The development of hematologic malignancies (MDS/AML) has been described in approximately 31% of ERCC6L2 germline-mutated patients at an average age of 35 years (range 2-59 years (n=12), Table 1) (7, 19, 24, 28–30).